Literature DB >> 28295219

Patterns, predictive factors and prognostic impact of multilevel metastasis in N1b papillary thyroid carcinoma.

S K Kim1, I Park1, N Hur1, J-H Choe1, J-H Kim1, J S Kim1.   

Abstract

BACKGROUND: The patterns, predictive factors and prognostic impact of multilevel metastasis in patients with N1b papillary thyroid carcinoma (PTC) were investigated.
METHODS: A retrospective review of patients with N1b PTC from a tertiary referral centre in Korea who underwent unilateral modified radical neck dissection was undertaken.
RESULTS: Of 658 patients, multilevel metastasis was found in 73·9 per cent; the most common type was metastasis in two levels. Tumour size per 0·1-cm increment (adjusted odds ratio (OR) 1·33, 95 per cent c.i. 1·08 to 1·64), microscopic extrathyroidal extension (adjusted OR 1·72, 1·10 to 2·71), gross extrathyroidal extension (adjusted OR 2·35, 1·24 to 4·46), unilateral central lymph node metastasis (adjusted OR 2·45, 1·53 to 3·92) and bilateral central lymph node metastasis (adjusted OR 4·06, 2·29 to 7·18) were independent predictors of multilevel metastasis. Only four-level metastasis significantly increased the risk of overall locoregional recurrence (LRR) (adjusted hazard ratio (HR) 7·41, 95 per cent c.i. 2·20 to 24·53) and lateral neck LRR (adjusted HR 7·22, 1·82 to 28·65), compared with one-level metastasis. Two subgroup analyses were conducted, showing that only three-level metastasis including metastasis in level V significantly increased the risk of overall LRR (adjusted HR 5·66, 1·20 to 26·75). In addition, having level V metastasis was an independent predictor of both overall (adjusted HR 3·26, 1·72 to 6·18; P < 0·001) and lateral neck (adjusted HR 3·28, 1·50 to 7·16; P = 0·003) LRR.
CONCLUSION: Level V metastasis rather than multilevel metastasis itself is associated with an increased risk of LRR. Patients with N1b PTC and level V metastasis require risk restratification and meticulous follow-up.
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28295219     DOI: 10.1002/bjs.10514

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  5 in total

1.  The optimal extent of lymph node dissection in N1b papillary thyroid microcarcinoma based on clinicopathological factors and preoperative ultrasonography.

Authors:  Xiao-Nan Liu; Yuan-Sheng Duan; Kai Yue; Yan-Sheng Wu; Wen-Chao Zhang; Xu-Dong Wang
Journal:  Gland Surg       Date:  2022-06

2.  Using a nomogram based on preoperative serum fibrinogen levels to predict recurrence of papillary thyroid carcinoma.

Authors:  Lei Jianyong; Li Zhihui; Gong Rixiang; Zhu Jingqiang
Journal:  BMC Cancer       Date:  2018-04-05       Impact factor: 4.430

3.  Nomogram for predicting level V lymph node metastases in papillary thyroid carcinoma with clinically lateral lymph node metastases: A large retrospective cohort study of 1037 patients from FDUSCC.

Authors:  Yunjun Wang; Qing Guan; Jun Xiang
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

4.  Features of Lymph Node Metastasis and Structural Recurrence in Papillary Thyroid Carcinoma Located in the Upper Portion of the Thyroid: A Retrospective Cohort Study.

Authors:  Yu Heng; Siqi Feng; Zheyu Yang; Wei Cai; Weihua Qiu; Lei Tao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-25       Impact factor: 5.555

Review 5.  Genetics, Diagnosis, and Management of Hürthle Cell Thyroid Neoplasms.

Authors:  David G McFadden; Peter M Sadow
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-10       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.